Canadian Scleroderma, PH Groups Collect Over 2,000 Letters Urging Access to PAH Treatments
Scleroderma Canada and the Pulmonary Hypertension Association of Canada have collected more than 2,000 letters signed by pulmonary arterial hypertension (PAH) patients, their caregivers and loved ones urging politicians to make all PAH treatments accessible as soon as possible through public funding. Health Canada approved Actelion’s Uptravi (selexipag) in January…